Grab This Altcoin Before Trump's Crypto Announcement

Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.

Rolf Classon Biography and Net Worth

Director of Perrigo

Rolf Classon has been a board member since August 2014. From October 2002 until his retirement in July 2004, Mr. Classon was Chairman of the Executive Committee of Bayer HealthCare AG, a subsidiary of Bayer AG. He served as President of Bayer Diagnostics from 1995 to 2002 and as Executive Vice President of Bayer Diagnostics from 1991 to 1995. Prior to 1991, Mr. Classon held various management positions with Pharmacia Corporation. Mr. Classon currently serves as Chairman of the Board of Directors of Perrigo Company plc and as a member of the Supervisory Board of Fresenius Medical Care. He was previously Chairman of the Board of Directors of Tecan Group Ltd., serving from 2009 until April 2018. Mr. Classon served as Chairman of the Board of Directors of Hill-Rom Corporation from 2006 until March 2018, also serving as Vice Chairman of the Board from 2003 through May 2005 and as interim chief executive officer from May 2005 until March 2006. From 2005 to 2015, Mr. Classon served as Chairman of the Board of Directors of Auxilium Pharmaceuticals, Inc., and as Vice Chairman from March 2005 to April 2005. He also previously served as a director of Sequanna Medical AG from 2016 to 2017; of Aerocrine AB, Stockholm from 2013 to 2015; of Millipore Corporation from 2005 to 2010; of Prometheus Laboratories Inc. from 2004 to 2010; and of Enzon Pharmaceuticals Inc. from 1997 to 2011.

Mr. Classon received his Chemical Engineering Certificate from the Gothenburg School of Engineering and a Business Degree from the Gothenburg University.

How do I contact Rolf A. Classon?: The corporate mailing address for Mr. Classon and other Perrigo executives is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. Perrigo can also be reached via phone at (531) 709-4000 and via email at [email protected]. Learn More on Rolf A. Classon's contact information.
Has Rolf A. Classon been buying or selling shares of Perrigo?: Rolf A. Classon has not been actively trading shares of Perrigo during the last ninety days. Most recently, on Thursday, December 2nd, Rolf A. Classon bought 2,800 shares of Perrigo stock. The stock was acquired at an average cost of $35.67 per share, with a total value of $99,876.00. Learn More on Rolf A. Classon's trading history.
Who are Perrigo's active insiders?: Perrigo's insider roster includes Bradley Alford (Director), Svend Andersen (EVP), Eduardo Bezerra (CFO), Rolf Classon (Director), James Dillard, III (EVP), Thomas Farrington (EVP), Alison Ives (EVP), Ronald Janish (EVP), Murray Kessler (CEO), Todd Kingma (VP), Patrick Lockwood-Taylor (President, CEO & Director), Geoffrey Parker (Director), Grainne Quinn (EVP), Theodore Samuels, II (Director), Raymond Silcock (CFO), Richard Sorota (EVP), and Robert Willis (EVP). Learn More on Perrigo's active insiders.
Are insiders buying or selling shares of Perrigo?: During the last twelve months, Perrigo insiders bought shares 4 times. They purchased a total of 18,990 shares worth more than $503,127.40. During the last twelve months, insiders at the sold shares 4 times. They sold a total of 67,852 shares worth more than $1,909,464.66. The most recent insider tranaction occured on December, 9th when Director Jeffrey B Kindler sold 17,598 shares worth more than $497,495.46. Insiders at Perrigo own 0.7% of the company. Learn More about insider trades at Perrigo.
Information on this page was last updated on 12/9/2024.

Rolf A. Classon Insider Trading History at Perrigo

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/2/2021	Buy	2,800	$35.67	$99,876.00

Rolf A. Classon Buying and Selling Activity at Perrigo

Perrigo Company Overview

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Today's Range

Now: $25.29

$24.97

$25.57

50 Day Range

MA: $26.80

$25.08

$28.91

2 Week Range

Now: $25.29

$23.89

$34.60

Volume

1,173,225 shs

Average Volume

1,589,455 shs

Market Capitalization

$3.45 billion

P/E Ratio

N/A

Dividend Yield

4.31%

Beta

0.52